Literature DB >> 2736179

Thymic atrophy and rebound enlargement following chemotherapy for testicular cancer.

P Hendrickx1, W Döhring.   

Abstract

Serial thoracic CT scans of 50 consecutive patients with testicular cancer were reviewed. In 30 of them with metastatic disease treated according to the Einhorn Scheme changes in thymic size caused by cytostatic agents were studied. During chemotherapy 78.6 per cent of all patients examined developed thymic atrophy, followed by rebound enlargement that reached its culminating point 13 months after initiation of treatment. After that a slow (approximately 2 years) involution process began, until the initial size or somewhat smaller size was re-achieved. The other 20 patients with no evidence of metastases, and therefore not treated with chemotherapy, showed no changes in thymic size. Rebound thymic enlargement following cytostatic therapy for metastatic testicular cancer should not be mistaken for lymphadenopathy.

Entities:  

Mesh:

Year:  1989        PMID: 2736179

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  3 in total

Review 1.  Influence of breast cancer on thymic function in mice.

Authors:  Diana M Lopez; Vijaya Charyulu; Becky Adkins
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Antagonist effect of Interleukin 1 receptor on normal thymopoiesis and thymus toxicity of 5-azacytidine in mouse.

Authors:  Hongjing Yu; Mingyuan Wu; Bin Wen; Ningyun Sun; Di Xiang; Jing Zhang; Shunying Zhu; Shunyan Weng; Yan Yu; Wei Han
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

3.  Comparative analysis of thymic subpopulations during different modes of atrophy identifies the reactive oxygen species scavenger, N-acetyl cysteine, to increase the survival of thymocytes during infection-induced and lipopolysaccharide-induced thymic atrophy.

Authors:  Shamik Majumdar; Vasista Adiga; Abinaya Raghavan; Supriya Rajendra Rananaware; Dipankar Nandi
Journal:  Immunology       Date:  2019-02-11       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.